Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Koelblinger

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|October 26, 2018
Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomasP Koelblinger, M Emberger, M Drach, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 24, 2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanomaN P Graf, P Koelblinger, N Galliker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 21, 2023
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignanciesR Lang, T Welponer, E Richtig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2024
Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysisM Brandlmaier, M Hoellwerth, T Silly, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of the European Academy of Dermatology and Venereology : JEADV|October 26, 2018
Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomasP Koelblinger, M Emberger, M Drach, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 24, 2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanomaN P Graf, P Koelblinger, N Galliker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 21, 2023
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignanciesR Lang, T Welponer, E Richtig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2024
Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysisM Brandlmaier, M Hoellwerth, T Silly, et al.
Pageof 1